학술논문
A dramatic course after the resection of an SMARCA4‐deficient undifferentiated tumour
Document Type
Report
Source
Respirology Case Reports. August 2022, Vol. 10 Issue 8
Subject
Language
English
Abstract
INTRODUCTION Thoracic SMARCA4‐deficient undifferentiated tumour (SMARCA4‐UT) is a high‐grade malignant neoplasm caused by the loss of function of SMARCA4, a key member of the SWItch/Sucrose‐NonFermentable (SWI/SNF) adenosine triphosphatase (ATPase)‐dependent chromatin [...]
: Thoracic SMARCA4‐deficient undifferentiated tumours are ordinarily found as a huge mass with systemic metastasis, and the prognosis is poor. The potential of immunotherapy for these unresectable tumours has been reported. An asymptomatic 68‐year‐old man with a smoking history had a left lung mass without distant metastasis and underwent complete resection. Two months after surgery, with no adjuvant therapy, he developed multiple distant metastases with aphasia and died 4 months after surgery. Adjuvant treatment may be necessary with immune checkpoint inhibitors, with a closer follow‐up to detect recurrence without symptoms.
: Thoracic SMARCA4‐deficient undifferentiated tumours are ordinarily found as a huge mass with systemic metastasis, and the prognosis is poor. The potential of immunotherapy for these unresectable tumours has been reported. An asymptomatic 68‐year‐old man with a smoking history had a left lung mass without distant metastasis and underwent complete resection. Two months after surgery, with no adjuvant therapy, he developed multiple distant metastases with aphasia and died 4 months after surgery. Adjuvant treatment may be necessary with immune checkpoint inhibitors, with a closer follow‐up to detect recurrence without symptoms.